Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Philip Strenger

Dermatology Monsey, NY Medical Doctor

NPI 1528074648 CMS profile 23277

29 College Rd, Monsey, NY 10952

Open in the dashboard

General payments

$11,180

441 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Philip Strenger of Monsey, NY is reported in the CMS Open Payments database as having received $11,180 across 441 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,654 65
2024 General $1,790 58
2023 General $2,203 71
2022 General $1,282 50
2021 General $1,468 70
2020 General $1,334 66
2019 General $1,450 61

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Philip Strenger
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Philip Strenger were reported at $1,654. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Philip Strenger Dermatology median Middle half National median
2019 $1,450 $454 $129–$1,240 $163
2020 $1,334 $235 $81–$756 $114
2021 $1,468 $377 $108–$1,108 $132
2022 $1,282 $514 $143–$1,391 $149
2023 $2,203 $607 $159–$1,674 $160
2024 $1,790 $751 $204–$1,903 $164
2025 $1,654 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $2,044 58 payments
  2. AbbVie, Inc. $1,517 69 payments
  3. Novartis Pharmaceuticals Corporation $1,484 70 payments
  4. Amgen Inc. $962 30 payments
  5. E.R. Squibb & Sons, L.L.C. $894 47 payments
  6. Incyte Corporation $543 11 payments
  7. LEO Pharma Inc. $505 24 payments
  8. Regeneron Healthcare Solutions, Inc. $438 18 payments
  9. Dermavant Sciences, Inc. $349 5 payments
  10. Genzyme Corporation $345 14 payments
  11. Other $2,101 95 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,843 437 payments
  2. Education $337 4 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $1,907 51 payments
  2. Otezla $915 28 payments
  3. SKYRIZI $899 45 payments
  4. SOTYKTU $879 46 payments
  5. HUMIRA $716 35 payments
  6. COSENTYX Immunology $644 33 payments
  7. COSENTYX Dermatology $533 26 payments
  8. STELARA $505 26 payments
  9. SIMPONI ARIA $483 23 payments
  10. SIMPONI $483 23 payments
  11. Other $5,647 233 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,376

Median for Dermatology: 534

Drug cost

$376,578

Median for Dermatology: $67,151

Branded share of claims

17.4%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 12 $262,295
Dupixent Pen Dupilumab Brand 20 $80,152
Calcipotriene Generic 63 $7,318
Metronidazole Generic 66 $4,680
Fluorouracil Generic 54 $4,100
Ciclopirox Ciclopirox Olamine Brand 132 $3,648
Ketoconazole Generic 201 $2,794
Clindamycin Phosphate Generic 48 $2,311
Triamcinolone Acetonide Generic 212 $1,517
Hydrocortisone Generic 144 $1,262

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$48,408

Medicare's payments for the services billed

Medicare patients

470

Average age 75

Services billed

1,058

215 women, 255 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 43%
Ischemic heart disease 29%
Diabetes 28%
Osteoporosis 20%
Cancer 16%
Atrial fibrillation 15%
Heart failure 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $310
$310 — —
VTAMA
  • Dermavant Sciences, Inc. $298
$298 — —
TREMFYA
  • Janssen Biotech, Inc. $284
$284 — —
OPZELURA
  • Incyte Corporation $280
$280 — —
SKYRIZI
  • AbbVie, Inc. $192
$192 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

441 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record